You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(600196.SH):FH-2001膠囊聯合斯魯利單抗注射液治療晚期實體瘤開展臨牀試驗獲批准

格隆匯7月8日丨復星醫藥(600196.SH)公佈,控股子公司江蘇星盛新輝醫藥有限公司於近日收到國家藥品監督管理局關於同意FH-2001膠囊聯合斯魯利單抗注射液治療晚期實體瘤開展臨牀試驗的批准。星盛新輝擬於條件具備後於中國境內(不包括港澳台地區)開展該治療方案的Ib/II期臨牀試驗。

該治療方案中所涉FH-2001膠囊為本集團自主研發的VEGFR/FGFR雙機制小分子抑制劑和PD-L1調節劑,擬主要用於治療晚期實體瘤;斯魯利單抗注射液(商品名:漢斯狀® )為本集團自主研發的創新型抗PD-1單抗。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account